568-P: Study of the Effect of PPARß/δ Activation on Diabetic Cardiomyopathy

ADEL ROSTAMI
DOI: https://doi.org/10.2337/db23-568-p
IF: 7.7
2023-06-20
Diabetes
Abstract:Diabetic cardiomyopathy (DC), the leading cause of death among people with diabetes, is definedas the occurrence of myocardial dysfunction in diabetic patients that is not directly attributableto coronary artery disease, hypertension, or valve disease. No specific drugs have yet beenapproved for treating DC and the use of Peroxisome Proliferator-Activated Receptor (PPAR)β/δagonists for the treatment of this disease show promise. Here, we examined as to whethertreatment with a PPARβ/δ agonist can prevent or ameliorate this pathology and as to whetherstreptozotozin (STZ)-induced DC is exacerbated in PPARβ/δ-deficient mice. In the STZ-induced mouse model of DC, an increase in cardiac fibrosis and an impairment inglucose and fatty acid metabolism was observed. Treatment with the PPARβ/δ agonist GW0742partially reduced the STZ-induced fibrosis, inflammation and metabolic disturbances, suggestingthat PPARβ/δ activation might be a potential target to prevent this disease suggesting a closerelation between inflammation and fibrosis in cardiac dysfunction of DC. In addition, we showthat PPARβ/δ suppression exacerbated hyperglycemia-induced DC and that PPARβ/δ activationthrough administration of agonists like GW501516 prevented the induction of some of themolecular mechanisms involved in the development of DC in these cells. Overall, these findingsdemonstrate the implication of PPARβ/δ in DC and suggest that its activation might be aneffective therapeutic tool for preventing or treating DC. Disclosure A.Rostami: None.
endocrinology & metabolism
What problem does this paper attempt to address?